ITEM
1A. RISK FACTORS
You
should carefully consider the following information about risks and uncertainties that may affect us or our business, together
with the other information appearing elsewhere in this Quarterly Report on Form 10-Q. If any of the following events, risks or
uncertainties actually occur, either alone or taken together, our business, financial condition, results of operations and future
growth prospects would likely be materially and adversely affected. These Risk Factors may be important to understanding any statement
in this Form 10-Q or elsewhere. The following information should be read in conjunction with the condensed consolidated financial
statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q.
We
will need to raise additional capital in future periods to continue operating our business, and such additional funds may not
be available on acceptable terms or at all.
We
do not generate any cash from operations and will need to raise additional funds in future periods in order to continue operating
our business. We estimate our cash requirements for the next 12 months to be approximately $20.2 million. As of January
31, 2017, we had cash and cash equivalents of approximately $20.5 million.
We
have a history of raising funds through offerings of our common stock and warrants to purchase our common stock. Although we are
exploring non-dilutive or less-dilutive ways of funding our operations, including but not limited to technology licensing and
partnership arrangements, we may need to continue to fund our operations through more dilutive public or private equity financings
in the near future, and we may also raise funds through debt financings or grants.
We
will require additional financing to fund our planned operations, including our proposed registration-directed combination study
of ImmunoPulse IL-12 as combination therapy with an anti-PD-1 therapy for the treatment of advanced metastatic melanoma, which
is expected to begin in the first half of 2017, developing and commercializing our intellectual property, seeking to license or
acquire new assets, researching and developing any potential patents, related compounds, and other intellectual property, funding
potential acquisitions, and supporting other clinical trials and seeking regulatory approval relating to our assets and any assets
we may develop or acquire in the future. Additional financing may not be available to us when needed or, if available, may not
be available on commercially reasonable terms. If we issue equity or convertible debt securities to raise additional funds, our
existing stockholders may experience further dilution, and the new equity or debt securities may have rights, preferences, and
privileges senior to those of our existing stockholders. If we incur debt, it may increase our leverage relative to our earnings
or to our equity capitalization, requiring us to pay additional interest expenses. Obtaining commercial loans, assuming those
loans would be available, would increase our liabilities and future cash commitments.
We
may not be able to obtain additional financing if the volatile and uncertain conditions in the capital and financial markets,
and more particularly the market for early-development-stage biotechnology and life science company stocks, persist. Weak economic
and capital markets conditions could result in increased difficulties in raising capital for our operations. We may not be able
to raise money through technology licensing and partnership arrangements or the sale of our equity securities or through borrowing
funds on terms we find acceptable. If we cannot raise the funds that we need, we may be unable to continue our operations, and
our stockholders could lose their entire investment in our Company.
We
may be unable to successfully develop and commercialize the assets we have acquired or develop and commercialize new assets and
product candidates.
Our
future results of operations will depend to a significant extent upon our ability to successfully develop and commercialize our
product candidates, such as the development of our ImmunoPulse® IL-2 platform through our proposed registration-directed trial
in melanoma. In addition, we plan to expand our clinical pipeline and to build our product portfolio through the acquisition or
licensing of new assets, product candidates or approved products. There are numerous difficulties inherent in acquiring, developing
and commercializing new products and product candidates, including difficulties related to:
|
●
|
obtaining
requisite regulatory approvals for such products in a timely manner or at all;
|
|
|
|
|
●
|
conducting
or completing clinical trials, including receiving incomplete, unconvincing, or equivocal clinical trials data;
|
|
|
|
|
●
|
successfully
identifying new potential product candidates;
|
|
|
|
|
●
|
developing
potential product candidates;
|
|
|
|
|
●
|
acquiring,
developing, testing, and manufacturing products in compliance with regulatory standards in a timely manner or at all;
|
|
|
|
|
●
|
being
subject to legal actions brought by our competitors, which may delay or prevent the development and commercialization of new
products;
|
|
|
|
|
●
|
being
dependent upon third parties to conduct certain aspects of clinical and preclinical studies;
|
|
|
|
|
●
|
significant
and unpredictable changes in the payor landscape, coverage, and reimbursement for any products we successfully develop and
commercialize; and
|
|
|
|
|
●
|
delays
or unanticipated costs, including those related to the foregoing.
|
As
a result of these and other difficulties, we may be unable to develop potential product candidates using our intellectual property,
and our potential products in development may not receive regulatory approvals in a timely manner or at all. If we do not acquire
or develop product candidates, if any of our product candidates are not approved in a timely manner or at all, or if any of our
product candidates, when acquired or developed and approved, cannot be successfully manufactured and commercialized, our operating
results would be adversely affected. In addition, we may not recoup our investment in developing products, even if we are successful
in commercializing those products. Our business expenditures may not result in the successful acquisition, development, or commercialization
of products that will prove to be commercially successful or result in the long-term profitability of our business.
If
the commencement or completion of clinical testing for product candidates based on our technology is delayed or prevented, that
could result in increased costs to us and delay or limit our ability to pursue regulatory approval or generate revenues.
Clinical
trials are very expensive, time-consuming, and difficult to design and implement. Even if we are able to complete our proposed
clinical trials and the results are favorable, clinical trials for product candidates based on our technology will continue for
several years and may take significantly longer than expected to complete.
Delays
in the commencement or completion of clinical testing, including but not limited to our proposed registration-directed study in
melanoma, could significantly affect our product development costs and business plan. We do not know whether our triple negative
breast cancer Phase II clinical trial, our melanoma combination investigator-initiated Phase II clinical trial, or our proposed
registration-directed clinical trial in melanoma will be completed on schedule, if at all. Currently, our Phase II clinical trials
in Merkel Cell carcinoma, melanoma, head and neck squamous cell carcinoma, and cutaneous T-Cell lymphoma are closed to enrollment
and have database lock, and they are proceeding to clinical study report writing. Our proposed registration-directed clinical
trial in melanoma is currently projected to be begin in calendar year 2017 and to complete enrollment in calendar year 2018. We
do not know whether any other pre-clinical or clinical trials, including Phase III clinical trials, will begin for this combination
therapy as it will be dependent on the phase II trial results. An investigator-initiated trial is a research effort in which the
investigator designs and implements the study and the investigator or the institution acts as the study sponsor. The trial sponsor
has control over the design, conduct and timing of such trials, and we have limited or no control over the commencement and completion
of such trials.
The
commencement and completion of clinical trials can be delayed or prevented for a number of reasons, including delays or issues
related to:
|
●
|
obtaining
clearance from the Food and Drug Administration, or FDA, or respective international regulatory body equivalents to commence
a clinical trial;
|
|
|
|
|
●
|
reaching
agreement on acceptable terms with prospective clinical research organizations, or CROs, clinical investigators, and trial
sites;
|
|
|
|
|
●
|
obtaining
institutional review board, or IRB, approval to initiate and conduct a clinical trial at a prospective site;
|
|
|
|
|
●
|
identifying,
recruiting and training suitable clinical investigators;
|
|
|
|
|
●
|
identifying,
recruiting and enrolling subjects to participate in clinical trials for a variety of reasons, including competition from other
clinical trial programs for similar indications;
|
|
|
|
|
●
|
retaining
patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy,
personal issues, death, or for any other reason they choose, or who are lost to further follow-up; and
|
|
|
|
|
●
|
identifying
and maintaining a sufficient supply of necessary products or product candidates, including those produced by third parties,
on commercially reasonable terms.
|
We
believe that we have planned and designed an adequate development strategy for our electroporation technology. However, the FDA
could determine that it is not satisfied with our plan or the details of our pivotal clinical trial protocols and designs and
put a clinical hold on the proposed trial. This could delay the commencement of the trial and would be a setback for the commercialization
strategy for ImmunoPulse® IL-12, and it could have a material adverse impact on our business and our stockholders’ investment
in our Company.
Additionally,
changes in applicable regulatory requirements and guidance may occur and we may need to amend our clinical trial protocols to
reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may
impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate,
any of our clinical trials, the commercial prospects for our product candidates may be harmed, which may have a material adverse
effect on our business, results of operations, financial condition and prospects.
To
the extent we conduct clinical trials of our product candidates in combination with third parties’ products, we will face
additional risks relating to supply of those products.
To
the extent that our strategy focuses on the combination of our product candidates with third parties’ products or product
candidates, such as anti-PD-1/PD-L1 products or product candidates, certain of our clinical studies may involve the combination
of our product candidates with the products or product candidates of third parties. This is true of our melanoma combination investigator-sponsored
Phase II clinical trial led by the University of California San Francisco to assess the combination of ImmunoPulse® IL-12
and Merck’s PD-1 antibody KEYTRUDA®, as well as our proposed registration-directed study in melanoma to assess the combination
of ImmunoPulse® IL-12 with an approved anti-PD-1 therapy in patients who have previously failed an anti-PD-1 therapy, which
we plan to begin in the first half of 2017. These studies involve additional risks due to their reliance on factors outside our
control, such as those relating to the availability and marketability of an approved anti-PD-1 therapy. If the marketability of
third-party products is impacted, or we are unable to secure and maintain a sufficient supply of such third-party products or
candidates on commercially reasonable terms, our clinical studies could be delayed or we could be forced to terminate these studies.
Such a delay or termination would have a material impact on our development strategy, business, results of operations, financial
conditions, and prospects.
Regulatory
authorities may not approve our product candidates or the approvals we secure may be too limited or too late for us to earn sufficient
revenues.
The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of our product candidates are subject
to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations
differ from country to country. The FDA and other foreign regulatory agencies can delay approval of or refuse to approve our product
candidates for a variety of reasons, including failure to meet safety and efficacy endpoints in our clinical trials. Our product
candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA,
may disagree with our or our partners’ trial design and our interpretation of data from preclinical studies and clinical
trials. Clinical trials of our product candidates may not demonstrate that they are safe and effective to the extent necessary
to obtain regulatory approvals.
Although
we have seen no systemic drug related adverse events to date, if we cannot adequately demonstrate through the clinical trial process
that a therapeutic product we are developing is safe and effective, regulatory approval of that product could be delayed or prevented,
which could impair our reputation, increase our costs and prevent us from earning revenues. Success in preclinical testing and
early clinical studies does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and
safety of an investigational drug. A number of companies in the pharmaceutical and biotechnology industries, including many with
greater resources and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results
in earlier clinical trials. Even if a product candidate is approved, it may be approved for fewer or more limited indications
than requested or the approval may be subject to the performance of significant post-marketing studies. In addition, regulatory
agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product
candidates. Any limitation, condition or denial of approval could have an adverse effect on our business, reputation and results
of operations.
Because
of the substantial competition we face, even if we are able to secure regulatory approval of our product candidates, delays in
such regulatory approval could delay or even prevent our ability to commercialize our product candidates. Even a failure to secure
accelerated regulatory approval under the FDA Accelerated Approval Program, or similar foreign programs, could lead us to reconsider
our development strategies and delay or prevent us from commercializing our product candidates.
If
we are unable to successfully recruit and retain qualified personnel, we may not successfully maintain or grow our business.
In
order to successfully implement and manage our business plan, we will depend upon, among other things, successfully recruiting
and retaining qualified executives, managers, scientists and other employees having relevant experience in life sciences and the
biotechnology industry. Competition for qualified individuals is intense, particularly in our geographical location where there
are several larger, more established life science and biotechnology companies that compete with us for talent. We also experience
competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely
on consultants and advisors, including scientific, clinical, and regulatory advisors, to assist us in formulating our research
and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may
have commitments under consulting or advisory contracts with other entities that may limit their availability to support us. If
we are not able to retain existing personnel and find, attract, and retain new qualified personnel on acceptable terms and in
a timely manner to coincide with our growth, we may not be able to successfully maintain or grow our business and our business
operations and prospects could suffer.
Additionally,
although we have employment agreements with each of our executive officers, these agreements are terminable by them at will and
we may not be able to retain any one or more of our executives. The loss of the services of any one or more members of our senior
management team, including recent changes within our management team, could (i) disrupt or divert our focus from pursuing our
business plan while we seek to recruit other executives, (ii) impact the perceptions of our employees, partners and investors,
and perceptions of prospective employees, partners and investors, regarding our business and prospects, (iii) cause us to incur
substantial costs in connection with managing transitions and recruiting suitable replacements, and (iv) delay or prevent the
development and commercialization of our product candidates. These and other potential consequences could cause significant harm
to our business, especially to the extent that we are not able to recruit suitable replacements in a timely manner.
Future
growth could strain our resources, and if we are unable to manage our growth, we may not be able to successfully implement our
business plan.
We
recently established a subsidiary corporation in Australia, and our business plan includes the continued growth of our operations,
including, but not limited to, the growth of our workforce and the expansion of our clinical studies beyond the U.S. Such growth
could place an additional strain on our management, administrative, operational, and financial infrastructure. Our future success
will depend, in part, upon the ability of our executive officers to manage growth effectively. This will require that we hire
and train additional personnel to support our expanding operations. International growth, such as the expansion of our clinical
trials to overseas clinical sites, will expose us to more complexity in our regulatory and accounting compliance and will expose
us to new risks and challenges inherent in international operations with which we may not be familiar, such as changing taxes
or duties, fluctuations in currency exchange rates, changes in applicable laws or policies, and potential for war or civil unrest.
In addition, we must continue to improve our operational, financial, and management controls and our reporting systems and procedures,
which can be made even more challenging while our operations are growing. If we fail to successfully manage our growth, we may
be unable to execute on our business plan.
Our
success depends in large part on our ability to protect our intellectual property using a combination of patents, trade secrets,
and confidentiality agreements. Certain of our patents will expire in the near future, and we may have difficulties protecting
our proprietary rights and technology and we may not be able to ensure their protection.
Our
commercial success will depend in large part on obtaining and maintaining patent, trademark, and trade secret protection of our
product candidates and their respective components, including devices, formulations, manufacturing methods, and methods of treatment,
as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making,
using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under
valid and enforceable patents or trade secrets that cover these activities. As we describe elsewhere in this Quarterly Report,
we have patent protection for components of our ImmunoPulse® product candidates. Our current device portfolio includes US7,412,284
and EP999867, which cover our current clinical device. These patents will expire between 2017 and 2018, at which point we can
no longer enforce these against third parties to prevent them from making, using, selling, offering to sell, or importing our
current clinical device. To the extent that pending or planned patent applications do not provide sufficient protection, this
could expose us to substantially more competition and have a material adverse impact on our business and our ability to commercialize
or license our technology and products.
In
addition, the coverage claimed in a patent application typically is significantly reduced before a patent is issued, either in
the United States or abroad. Consequently, any of our pending or future patent applications may not result in the issuance of
patents and any patents issued may be subjected to further proceedings limiting their scope and may in any event not contain claims
broad enough to provide meaningful protection. Any patents that are issued to us or our future collaborators may not provide significant
proprietary protection or competitive advantage and may be circumvented or invalidated. In addition, unpatented proprietary rights,
including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed
by a third party or if their secrecy is lost. Further, because development and commercialization of our potential product candidates
can be subject to substantial delays, our patents may expire or provide only a short period of protection, if any, following any
future commercialization of products. Moreover, obtaining and maintaining patent protection depends on compliance with various
procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection
could be reduced or eliminated for non-compliance with these requirements. If any of our patents are found to be invalid or unenforceable,
or if we are otherwise unable to adequately protect our rights, it could have a material adverse impact on our business and our
ability to commercialize or license our technology and products.
We
have never generated, and may never generate, profit from our operations.
We
have not generated any revenue from operations since our inception. During the quarter ended January 31, 2017, we incurred a net
loss of approximately $5.4 million. From inception through January 31, 2017, we have incurred an aggregate net loss of approximately
$84.5 million. We expect to tightly manage our monthly operating expenses; however, we expect our cumulative operating expenses
will continue to increase as we further our development activities and pursue FDA approval for our product candidates.
Because
of the numerous risks and uncertainties associated with our product development and commercialization efforts, we are unable to
predict the extent of our future losses or when or if we will become profitable, and it is possible we will never commercialize
any of our product candidates or become profitable. Our failure to obtain regulatory approval and successfully commercialize any
of our product candidates would have a material adverse effect on our business, results of operations, financial condition, and
prospects and could result in our inability to continue operations.
We
rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their duties or meet
expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business
could be substantially harmed.
We
have entered into, and expect to continue to enter into, agreements with third-party clinical research organizations, or CROs,
to help us manage critical aspects of the clinical trials we sponsor. We currently rely on these third parties for the execution
of certain of our clinical and pre-clinical studies, and we only control certain aspects of their activities. We, and our CROs,
are required to comply with the current FDA Code of Federal Regulations for Conducting Clinical Trials and Good Clinical Practice,
and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines.
The FDA and similar foreign regulators enforce these Good Clinical Practice regulations through periodic inspections of trial
sponsors, principal investigators, CRO trial sites, laboratories, and any entity having to do with the completion of the study
protocol and processing of data. If we, or our CROs, fail to comply with applicable Good Clinical Practice regulations, the data
generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before
approving our marketing applications. Upon inspection, the FDA and similar foreign regulators may determine that our clinical
trials are not compliant with Good Clinical Practice regulations. Our failure to comply with these regulations may require us
to repeat clinical trials, which would increase costs and delay the regulatory approval process.
If
any of our relationships with third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs
on commercially reasonable terms, on a timely basis, or at all. If CROs do not successfully carry out their contractual duties
or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they
obtain is compromised due to failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our
clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates
could be harmed, our costs could increase, and our ability to generate additional revenues could be delayed.
We
have participated in, and continue to participate in, clinical trials conducted under an approved investigator-sponsored investigational
new drug (IND) application, and correspondence and communication with the FDA pertaining to these trials will strictly be between
the investigator and the FDA.
We
have participated in, and continue to participate in, clinical trials conducted under an approved investigator-sponsored investigational
new drug application, including our melanoma combination investigator-sponsored Phase II clinical trial led by the University
of California San Francisco to assess the combination of ImmunoPulse® IL-12 and Merck’s PD-1 antibody KEYTRUDA®.
Regulations and guidelines imposed by the FDA with respect to IND applications include a requirement that the sponsor of a clinical
trial provide ongoing communication with the agency as it pertains to safety of the treatment. This communication can be relayed
to the agency in the form of safety reports, annual reports, or verbal communication at the request of the FDA. Accordingly, it
is the responsibility of each investigator (as the sponsor of the trial) to be the point of contact with the FDA. The communication
and information provided by the investigator may not be appropriate and accurate, and the investigator has the ultimate responsibility
and final decision-making authority with respect to submissions to the FDA. This may result in reviews, audits, delays, or clinical
holds by the FDA ultimately affecting the timelines for these studies and potentially risking the completion of these trials.
We
are an early-stage, pre-commercial company with a limited operating history, which may hinder our ability to successfully generate
revenues and meet our objectives.
We
are an early-stage, pre-commercial company with only a limited operating history upon which to base an evaluation of our current
business and future prospects and how we will respond to competitive, financial, or technological challenges. Although we are
investigating licensing and partnering opportunities with respect to raising additional capital, we are not currently planning
on generating any significant near term revenue from those potential opportunities; therefore, the revenue generating potential
from our business is unproven. In addition, because of our limited operating history, we have limited insight into trends that
may emerge and affect our business. Errors may be made in predicting and reacting to relevant business trends and we will be subject
to the risks, uncertainties, and difficulties frequently encountered by early-stage companies in evolving markets. We may not
be able to successfully address any or all of these risks and uncertainties. Failure to adequately do so could cause our business,
results of operations, and financial condition to suffer or fail.
We
have not commercialized any of our product candidates. Our ability to generate revenues from any of our product candidates will
depend on a number of factors, including our ability to successfully complete clinical trials, obtain necessary regulatory approvals,
and negotiate arrangements with third parties to help finance the development of, and market and distribute, any product candidate
that receives regulatory approval. In addition, even if we achieve regulatory approval for one or more of our product candidates,
we will be subject to the risk that the marketplace may not accept our products in sufficient levels for us to achieve profitability.
Our
common stock has low trading volume and the price of our common stock has been, and will likely continue to be, highly volatile.
Trading
of our common stock is frequently highly volatile, with low trading volume. We have experienced, and are likely to continue experiencing,
significant fluctuations in the stock price and trading volume. There is no assurance that a sufficient market will develop in
our stock, in which case it could be difficult for stockholders to sell their stock. Furthermore, the volatility of our stock
price could negatively impact our ability to raise capital or acquire businesses or technologies.
In
addition to the risks and uncertainties described in this section of this Quarterly Report, other factors affecting the trading
price and trading volume of our common stock may include:
|
●
|
adverse
research and development or clinical trial results;
|
|
|
|
|
●
|
conducting
open-ended clinical trials which could lead to results (success or setbacks) being obtained by the public prior to a formal
announcement by us;
|
|
|
|
|
●
|
our
inability to obtain additional capital;
|
|
|
|
|
●
|
announcement
that the FDA denied our request to approve our products for commercialization in the United States, or similar denial by other
regulatory bodies which make independent decisions outside the United States;
|
|
|
|
|
●
|
potential
negative market reaction to the terms or volume of any issuance of shares of our stock or other securities to new investors
or service providers or to employees or directors;
|
|
|
|
|
●
|
sales
of substantial amounts of our common stock, or the perception that substantial amounts of our common stock will be sold, by
our stockholders in the public market;
|
|
|
|
|
●
|
declining
working capital to fund operations, or other signs of apparent financial uncertainty;
|
|
|
|
|
●
|
significant
advances made by competitors that adversely affect our potential market position; and
|
|
|
|
|
●
|
the
loss of key personnel and the inability to attract and retain additional highly-skilled personnel.
|
If
outstanding options and warrants to purchase shares of our common stock are exercised or outstanding restricted stock units vest
or settle, the interests of our stockholders could be diluted.
In
addition, as of January 31, 2017 we have outstanding (i) options to purchase 2,590,543 shares of common stock, (ii) warrants to
purchase 11,286,995 shares of our common stock, including Series B Warrants to purchase 2,764,000 shares of common stock at an
exercise price of $0.01 per share, and (iii) 590,000 restricted stock units. In addition, we have as of January 31, 2017, 2,089,457
shares reserved for future issuance under our 2011 Stock Incentive Plan and 463,580 shares reserved for future issuance under
our 2015 Employee Stock Purchase Plan. The exercise of options and warrants, the vesting and settlement of restricted stock units,
the issuance of additional shares of common stock or other awards under our 2011 Stock Incentive Plan and the sale of any resulting
shares of our common stock in connection with the foregoing, could have an adverse effect on the market for our common stock,
including the price that an investor could obtain for their shares. Investors may experience dilution in the net tangible book
value of their investment upon the exercise of outstanding options and warrants or the vesting of restricted stock units granted
under our stock option plans, and options, restricted stock units and warrants that may be granted or issued in the future. In
addition, in future periods, we may elect to reduce the exercise price of outstanding warrants as a means of providing additional
financing to us.
If
our common stock is delisted from The Nasdaq Capital Market or we are found noncompliant with Nasdaq regulations, our stock’s
market price and liquidity could be negatively impacted.
Our
listing on The Nasdaq Capital Market (“NASDAQ”) is contingent upon our meeting all of NASDAQ’s continued listing
requirements. If we are found noncompliant by NASDAQ, or if our common stock is delisted from NASDAQ, our stock price could be
negatively impacted, our stock’s liquidity could be reduced, and our ability to raise capital in the future may be limited
or prevented.
The
biotechnology industry is highly competitive and our competitors tend to be larger and have been in business longer than us.
The
biotechnology industry has an intensely competitive environment that will require an ongoing, extensive search for technological
innovations and the ability to market products effectively, including the ability to communicate the effectiveness, safety, and
value of products to healthcare professionals in private practice, group practices, and payors in managed care organizations,
group purchasing organizations, and Medicare & Medicaid services.
We
face competition from a number of sources, including large pharmaceutical companies, biotechnology companies, academic institutions,
government agencies and private and public research institutions. We are smaller than many of our competitors. Many of our competitors
have been in business for a longer period of time than us, have a greater number of products on the market, and have greater financial
and other resources than we do. Furthermore, recent trends in this industry are that large drug companies are consolidating into
a smaller number of very large entities, which further concentrates financial, technical, and market strength and increases competitive
pressure in the industry.
Our
competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection
or other intellectual property rights that limit or block us from developing or commercializing our product candidates. If we
are able to obtain regulatory approval of our product candidates or any assets we may acquire in the future, we will face competition
from products currently marketed by larger competitors that address our targeted indications. If we directly compete with these
very large entities for the same markets and/or products, their financial strength could prevent us from capturing a share of
those markets. Our competitors may also develop products that are more effective, more useful, better tolerated, subject to fewer
or less severe side effects, more widely prescribed or accepted, or less costly than ours and may also be more successful than
us in manufacturing and marketing their products.
We
also face competition from product candidates that are or could be under development. We expect our product candidates, if approved
and commercialized, to compete on the basis of, among other things, product efficacy and safety, time to market, price, patient
reimbursement by third-party payors, extent of adverse side effects, and convenience of treatment procedures. We may not be able
to effectively compete in one or more of these areas.
If
we are unable to compete effectively with the marketed therapeutics of our competitors or if such competitors are successful in
developing products that compete with our potential product candidates, our business, results of operations, financial condition,
and prospects may be materially adversely affected.
Our
failure to successfully develop, acquire, and market additional product candidates or approved products would impair our ability
to grow.
Our
business plan includes the expansion of our clinical pipeline and our product portfolio through the acquisition, in-license, development,
and/or marketing of additional products and product candidates. The success of our efforts to expand our clinical pipeline and
to build our product portfolio will depend in significant part on our ability to successfully identify, select and acquire promising
product candidates and products.
The
process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product can be
lengthy and complex. Other companies, including many of our competitors with substantially greater financial, marketing and sales
resources, may compete with us for the license or acquisition of product candidates and approved products. Our experience in making
acquisitions, entering collaborations and in-licensing product candidates is limited, and we have limited resources to identify
and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current
infrastructure. We may incorrectly judge the value or worth of an acquired or in-licensed product candidate, approved product
or other asset. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed,
or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product
candidates on terms that we find acceptable, or at all.
In
addition, future acquisitions may entail numerous operational and financial risks, including:
|
●
|
exposure
to unknown liabilities;
|
|
|
|
|
●
|
disruption
of our business and diversion of our management’s time and attention to manage the acquisition and develop acquired
products or technologies;
|
|
|
|
|
●
|
incurrence
of substantial debt or dilutive issuances of securities to pay for acquisitions;
|
|
|
|
|
●
|
higher
than expected acquisition and integration costs;
|
|
|
|
|
●
|
increased
amortization expenses;
|
|
|
|
|
●
|
difficulty
and cost in combining the operations and personnel of any acquired business with our operations and personnel;
|
|
|
|
|
●
|
impairment
of relationships with key suppliers or customers of any acquired business due to changes in management and ownership; and
|
|
|
|
|
●
|
inability
to retain key employees of any acquired business.
|
Any
collaboration arrangement that we have entered into or may enter into in the future may not be successful, which could adversely
affect our ability to develop and commercialize our current and potential future product candidates.
We
may seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of
our current and potential future product candidates, including our pursuit of combination trials to develop and commercialize
our product candidates as combination products. Drug/device combination products are particularly complex, expensive and time-consuming
to develop due to the number of variables involved in the final product design, including ease of patient and doctor use, maintenance
of clinical efficacy, reliability and cost of manufacturing, regulatory approval requirements and standards, and other important
factors. Thereafter, such products face continued risk and uncertainty related to manufacturing and supply until the commercial
supply chain is validated and proven.
We
will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate
collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document and implement. We may
not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose
to enter into such arrangements, or the terms of such arrangements may not be favorable to us. If and when we collaborate with
a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control
over the future success of that product candidate to the third party. The success of our collaboration arrangements will depend
heavily on the efforts and activities of our collaborators, who would likely have significant discretion in determining the efforts
and resources that they will apply to these collaborations.
Disagreements
between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays
in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither party has final decision-making authority. Collaborations
with third parties often are terminated or allowed to expire by the third party, which would adversely affect us financially and
could harm our business reputation.
We
may incur liability if our promotions of product candidates are determined, or are perceived, to be inconsistent with regulatory
guidelines.
The
FDA provides guidelines with respect to appropriate product promotion and continuing medical and health education activities.
Although we endeavor to follow these guidelines, the FDA or the Office of the Inspector General: U.S. Department of Health and
Human Services may disagree, and we may be subject to significant liability, including civil and administrative remedies as well
as criminal sanctions. In addition, management’s attention could be diverted and our reputation could be damaged.
If
we and the contract manufacturers upon whom we rely fail to produce our systems and product candidates in the volumes that we
require on a timely basis, or fail to comply with stringent regulations, we may face delays in the development and commercialization
of our electroporation equipment and product candidates.
We
currently assemble certain components of our electroporation systems, which is our delivery mechanism for our biologic to a patient’s
cell. We utilize the services of contract manufacturers to manufacture the remaining components of these systems and our product
supplies for clinical trials. We expect to increase our reliance on third party manufacturers if and when we commercialize our
product candidates and systems. The manufacture of our systems and product supplies requires significant expertise and capital
investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter
difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production
costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing,
shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. If we or
our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations
to us, our ability to provide our electroporation equipment to our partners and products to patients in our clinical trials or
to commercially launch a product would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could
delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program, and, depending
upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely.
In
addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection
program. These requirements include, among other things, quality control, quality assurance, and the generation and maintenance
of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other
FDA, state, and foreign regulatory requirements. We have little control over our manufacturers’ compliance with these regulations
and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production,
suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product
is compromised due to our or our manufacturers’ failure to adhere to applicable laws or for other reasons, we may not be
able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries
sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals, or commercialization
of our products, entail higher costs, or result in our being unable to effectively commercialize our products. Furthermore, assuming
we are successful in commercializing one or more of our product candidates, if our manufacturers fail to deliver the required
commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be
unable to meet demand for our products and would lose potential revenues.
We
may not be successful in executing our strategy for the commercialization of our product candidates. If we are unable to successfully
execute our commercialization strategy, we may not be able to generate significant revenue.
We
intend to advance a commercialization strategy that leverages previous in-depth clinical experiences, previous CE (
Conformité
Européene
) approvals, and late-stage clinical studies in the United States. This strategy includes seeking approval
from the FDA and similar foreign regulators to initiate pivotal registration studies in the United States and abroad, including
studies in select rare cancers that have limited, adverse, or no therapeutic alternatives. This strategy also includes expanding
the addressable markets for our therapies through the addition of relevant indications. Our commercialization plan also includes
partnering and/or co-developing our technology in developing regions, such as Eastern Europe and Asia, where local resources are
best leveraged and appropriate collaborators can be secured.
Our
commercialization strategy may include the establishment of our own sales, marketing, and distribution capabilities to market
products to our target markets. Developing these capabilities would require significant expenditures on personnel and infrastructure.
While we intend to market products that are aimed at a small patient population, we might not be able to create an effective sales
force around even a niche market. In addition, some of our product candidates could require a large sales force to call on, educate,
and support physicians and patients. We could desire in the future to enter into collaborations with one or more pharmaceutical
companies to sell, market, and distribute such products, but we may not be able to enter into any such arrangement on acceptable
terms, if at all. Any collaboration we do enter into may not be effective in generating meaningful product royalties or other
revenues for us.
We
may not be able to implement a commercialization strategy as we have planned. Further, we have not proven our ability to succeed
in the biotechnology industry and are not certain that our implementation strategy, if implemented correctly, would lead to significant
revenue. If we are unable to successfully implement our commercialization plans and drive adoption by patients and physicians
of our potential future products through our sales, marketing, and commercialization efforts, then we will not be able to generate
significant revenue which will have a material adverse effect on our business, results of operations, financial condition, and
prospects.
If
any product candidate for which we receive regulatory approval does not achieve broad market acceptance or coverage by third-party
payors, our revenues may be limited.
The
commercial success of any potential product candidates for which we obtain marketing approval from the FDA or other regulatory
authorities will depend upon the acceptance of these products by physicians, patients, healthcare payors, and the medical community.
Coverage and reimbursement of our approved product by third-party payors is also necessary for commercial success. The degree
of market acceptance of any potential product candidates for which we may receive regulatory approval will depend on a number
of factors, including:
|
●
|
our
ability to provide acceptable evidence of safety and efficacy;
|
|
|
|
|
●
|
acceptance
by physicians and patients of the product as a safe and effective treatment;
|
|
|
|
|
●
|
the
prevalence and severity of adverse side effects;
|
|
●
|
limitations
or warnings contained in a product’s FDA-approved labeling or other regulator-approved labeling;
|
|
|
|
|
●
|
the
clinical indications for which the product is approved;
|
|
|
|
|
●
|
availability
and perceived advantages of alternative treatments;
|
|
|
|
|
●
|
any
negative publicity related to our or our competitors’ products;
|
|
|
|
|
●
|
the
effectiveness of our or any current or future collaborators’ sales, marketing, and distribution strategies;
|
|
|
|
|
●
|
pricing
and cost effectiveness;
|
|
|
|
|
●
|
our
ability to obtain sufficient third-party payor coverage or reimbursement; and
|
|
|
|
|
●
|
the
willingness of patients to pay out-of-pocket in the absence of third-party payor coverage.
|
Certain
characteristics of our ImmunoPulse® platform, including its reliance on electroporation technology, intratumoral delivery,
and surface-accessible tumors, may impact market acceptance of the platform.
Cost
containment is a primary trend in the U.S. healthcare industry. Third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular products and procedures. Increasingly, third-party payors are requiring
that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.
In addition, recent trends in U.S. politics suggest that we may see changes to the U.S. healthcare insurance framework. For all
of these reasons and more, we cannot guarantee that coverage and reimbursement will be available for any product that we commercialize
and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand
for, or the price of, any product for which we obtain marketing approval. If coverage and reimbursement is not available or is
available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully
develop.
In
addition, the regulations that govern marketing approvals, pricing, coverage and reimbursement for new therapeutic products vary
widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many
countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.
As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations
that delay our commercial launch of the product and negatively impact the revenue we are able to generate from the sale of the
product in that country.
Physicians,
patients, and third-party payors may be less accepting of our product candidates due to certain characteristics of our product
candidates. They may have concerns, for example, about the complexity inherent in a combination therapy approach, or about the
clinical application of electroporation technology which is less prevalent in the United States. A lack of acceptance of our product
candidates could prevent us from successfully commercializing product candidates for which we secure regulatory approval.
Our
efforts to educate the medical community and third-party payors on the benefits of any of our potential product candidates may
require significant resources and may never be successful. If our potential products do not achieve an adequate level of acceptance
by physicians, third-party payors, and patients, physicians may not choose to utilize our product and we may not generate sufficient
revenue from these products to become or remain profitable.
Extensive
industry regulation has had, and will continue to have, a significant impact on our business, especially our product development,
manufacturing, and distribution capabilities.
All
biotechnology companies are subject to extensive, complex, costly, and evolving government regulation. For the U.S., these regulations
are principally administered by the FDA and to a lesser extent by the United States Drug Enforcement Agency and state government
agencies, as well as by various regulatory agencies in foreign countries where products or product candidates are being manufactured
and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act, and other federal statutes and regulations,
and similar foreign statutes and regulations, govern or influence the testing, manufacturing, packing, labeling, storing, record
keeping, safety, approval, advertising, promotion, sale, and distribution of our products. Under these regulations, we may become
subject to periodic inspection of our facilities, procedures, and operations and/or the testing of our product candidates and
products by the FDA, the Drug Enforcement Agency, and other authorities, which conduct periodic inspections to confirm that we
are in compliance with all applicable regulations. In addition, the FDA and foreign regulatory agencies conduct pre-approval and
post-approval reviews and plant inspections to determine whether our systems and processes are in compliance with cGMP and other
regulations. Following such inspections, the FDA or other agency may issue observations, notices, citations, and/or warning letters
that could cause us to modify certain activities identified during the inspection. To the extent that we successfully commercialize
any product, we may also be subject to ongoing FDA obligations and continued regulatory review with respect to manufacturing,
processing, labeling, packaging, distribution, storage, advertising, promotion, and recordkeeping for the product. Additionally,
we may be required to conduct potentially costly post-approval studies and report adverse events associated with our products
to the FDA and other regulatory authorities. Unexpected or serious health or safety concerns would result in labeling changes,
recalls, market withdrawals, or other regulatory actions.
The
range of possible sanctions includes, among others, FDA issuance of adverse publicity, product recalls or seizures, fines, total
or partial suspension of production and/or distribution, suspension of the FDA’s review of product applications, enforcement
actions, injunctions, and civil or criminal prosecution. Any such sanctions, if imposed, could have a material adverse effect
on our business, operating results, financial condition, and cash flows. Under certain circumstances, the FDA also has the authority
to revoke previously granted drug approvals. Similar sanctions as detailed above may be available to the FDA under a consent decree,
depending upon the actual terms of such decree. If internal compliance programs do not meet regulatory agency standards or if
compliance is deemed deficient in any significant way, it could materially harm our business.
Moreover,
the regulations, policies, or guidance of the FDA or other regulatory agencies may change and new or additional statutes or government
regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate
post-approval activities. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market
our potential product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.
If
we fail to comply with applicable healthcare laws and regulations, we could face substantial penalties and our business, operations,
prospects and financial condition could be adversely affected.
Although
our staff and internal/external legal teams strive to comply with all applicable healthcare laws and regulations, the regulatory
environment is constantly changing and certain federal and state healthcare laws and regulations may affect our business, including:
|
●
|
the
federal Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration,
directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering
of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;
|
|
|
|
|
●
|
federal
false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be
presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;
|
|
|
|
|
●
|
the
Patient Protection and Affordable Care Act expands the government’s investigative and enforcement authority and increases
the penalties for fraud and abuse, including amendments to both the False Claims Act and the Anti-Kickback Statute to make
it easier to bring suit under those statutes;
|
|
|
|
|
●
|
the
federal Health Insurance Portability and Accountability Act of 1996 which prohibits executing a scheme to defraud any healthcare
benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating
to the privacy, security and transmission of individually identifiable health information;
|
|
|
|
|
●
|
the
Federal Food, Drug and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers
from marketing drug products for off-label use and regulates the distribution of drug samples; and
|
|
|
|
|
●
|
state
law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or
services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security
of health information in certain circumstances, many of which differ from each other in significant ways and often are not
preempted by Health Insurance Portability and Accountability Act, thus complicating compliance efforts.
|
Additionally,
the compliance environment is changing, with more states, such as California and Massachusetts, mandating implementation of compliance
programs, compliance with industry ethics codes, and spending limits, and other states, such as Vermont, Maine, and Minnesota
requiring reporting to state governments of gifts, compensation, and other remuneration to physicians. Under the Affordable Care
Act, pharmaceutical companies must record any transfers of value made to doctors and teaching hospitals and to disclose such data
to the U.S. Department of Health and Human Services. These laws all provide for penalties for non-compliance. The shifting regulatory
environment, including proposed revisions to or replacement of the Affordable Care Act, along with the requirement to comply with
multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run
afoul of one or more laws. It also may adversely affect:
|
●
|
our
ability to set a price we believe is fair for our products;
|
|
|
|
|
●
|
our
ability to generate revenues and achieve or maintain profitability;
|
|
|
|
|
●
|
the
availability of capital; and
|
|
|
|
|
●
|
our
ability to obtain timely approval of our products.
|
Further,
even though we do not and will not control referrals of healthcare services or bill directly to third-party payors, certain federal
and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights may be applicable to our business.
We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states
in which we conduct our business.
To
the extent that we operate in a foreign country or any product we make is sold in a foreign country, we also may be subject to
foreign laws and regulations.
If
we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that
apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring
of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability
to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation
of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws
may prove costly and have a significant adverse effect on us.
We
face potential product liability exposure and if successful claims are brought against us, we may incur substantial liability.
The
clinical use of our product candidates exposes us to the risk of product liability claims. Any side effects, manufacturing defects,
misuse, or abuse associated with our product candidates could result in injury to a patient or even death. In addition, a liability
claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims
may be brought against us by consumers, healthcare providers, pharmaceutical companies, or others coming into contact with our
product candidates, among others.
Regardless
of merit or potential outcome, product liability claims against us may result in, among other effects, the inability to commercialize
our product candidates, impairment of our business reputation, withdrawal of clinical trial participants, and distraction of management’s
attention from our primary business. If we cannot successfully defend ourselves against product liability claims, we could incur
substantial liabilities.
We
may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions
to our management.
From
time to time, we may consider engaging in strategic transactions, such as acquisitions of companies, asset purchases, and out-licensing
or in-licensing of products, product candidates or technologies. Any such transaction may require us to incur non-recurring or
other charges, may increase our near and long-term expenditures, and may pose significant integration challenges or disrupt our
management or business, which could adversely affect our operations and financial results. For example, these transactions may
entail numerous operational and financial risks, including, among others, exposure to unknown liabilities, disruption of our business
and diversion of our management’s time and attention in order to develop acquired products, product candidates, or technologies,
difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel, and
inability to retain key employees of any acquired businesses. The pursuit of such transactions could also create a distraction
for management and entail increased expenses in connection with the pursuit, evaluation, and negotiation of such transactions.
Further, such transactions could result in substantial dilution of our stockholders. Accordingly, although we may not choose to
undertake or may not be able to successfully complete any transactions of the nature described above, the pursuit of such transactions,
and any transactions that we do complete, could have a material adverse effect on our business, results of operations, financial
condition, and prospects.
Our
business and operations could suffer in the event of cyber-attacks or system failures.
Despite
the implementation of security measures, our internal computer systems and those of our current and any future partners, contractors,
and consultants are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism,
war, and telecommunication and electrical failures. System failures, accidents, or security breaches could cause interruptions
in our operations, and could result in a material disruption of our commercialization activities, development programs and our
business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial
data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase
our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of,
or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability and the commercialization of any potential product candidate could be delayed or prevented.
If
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results. As
a result, current and potential stockholders could lose confidence in our financial reporting, which could harm our business.
Effective
internal controls are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports,
our operating results could be misstated, our reputation may be harmed, and the trading price of our stock could be negatively
affected. Our controls over financial processes and reporting may not continue to be effective, or we may identify significant
deficiencies or material weaknesses in our internal controls in the future. Any failure to remediate any significant deficiencies
or material weaknesses or to implement required new or improved controls, or difficulties encountered in their implementation,
could harm our operating results, cause us to fail to meet our reporting obligations, or result in material misstatements in our
financial statements or other public disclosures. Inferior internal controls could also cause investors to lose confidence in
our reported financial information, which could have a negative effect on the trading price of our stock.
Maintaining
compliance with our obligations as a public company may strain our resources and distract management, and if we do not remain
compliant our stock price may be adversely affected.
We
are required to evaluate our internal control systems in order to allow management to report on our internal controls as required
by Section 404 of the Sarbanes-Oxley Act of 2002, and our management is required to attest to the adequacy of our internal controls.
The U.S. Financial Accounting Standards Board and International Accounting Standards Board have been working together since 2002
to achieve convergence of and U.S. generally accepted accounting principles, or GAAP, and International Financial Reporting Standards,
or IFRS. As GAAP and IFRS converge into a single set of high quality standards, implementing the new standards could require us
to make adjustments to our previously reported financial statements and could require us to make significant investments in training,
hiring, consulting, and information technology, among other investments. All of these and other reporting requirements and heightened
corporate governance obligations that we face, or will face, will further increase the cost to us, perhaps substantially, of remaining
compliant with our obligations under the Securities Exchange Act of 1934, as amended and other applicable laws, including the
Sarbanes-Oxley Act and the Dodd-Frank Act of 2010.
We
may not be able to realize value from, or otherwise preserve and utilize, our net operating loss carryforwards.
Significant
equity restructuring often results in an Internal Revenue Section 382 ownership change that limits the future use of net operating
loss carryforwards and other tax attributes. In the event that we undergo such an ownership change, our net operating loss carryforwards
generated prior to the ownership change would be subject to annual limitations, which could reduce, eliminate, or defer the utilization
of these losses. Further, the recognition and measurement of our net operating loss carryforwards may include estimates and judgments
by our management, and the Internal Revenue Service has not audited or otherwise validated the amount of our net operating loss
carryforwards. Additionally, legislative changes could negatively impact our ability to use any tax benefits associated with our
net operating loss carryforwards. If we put in place limitations on ownership of our common stock or adopt a shareholder rights
plan to preserve our ability to use net operating loss carryforwards, this could deter potential buyers of our common stock and
adversely impact the trading price of our common stock.
Our
licensed intellectual property may not provide us with sufficient rights and may not prevent competitors from pursuing similar
technology.
We
have exclusively licensed certain technology and related assets that cover our current therapeutic methods. Patents for technology
we have licensed are still in force in certain jurisdictions, and the technology patent family will expire between 2017 and 2018.
Method-of-use patents are granted in certain jurisdictions and applications are pending in others, with an expiry between 2025
and 2027. These method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent
a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope
of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians
may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use
patents, the practice is common and such infringement is difficult to prevent or prosecute.
We
have entered into a cross-license agreement for certain electroporation technology with Inovio Pharmaceuticals, Inc., or Inovio.
Under the terms of the cross-license agreement, Inovio granted to us a non-exclusive, worldwide license to certain electroporation
patents held by Inovio. In exchange, we granted to Inovio an exclusive license to our acquired technology in a limited field of
use. While we do not currently substantially rely on the intellectual property we have non-exclusively licensed from Inovio, our
product candidates may, in the future, utilize this intellectual property. This license is non-exclusive and Inovio may use its
technology to compete with us. As there are no restrictions on Inovio’s ability to license their technology to others, Inovio
could license to others, including our competitors, the intellectual property rights covered by their license to us, including
any of our improvements to the licensed intellectual property. Either party may terminate the cross-license agreement with 30
days’ notice; and, if either party were to terminate the cross-license agreement, they would no longer have the right to
use intellectual property that is subject to the cross license.
We
may incur substantial costs as a result of litigation or other proceedings relating to protection of our patent and other intellectual
property rights, and we may be unable to successfully protect our rights to our potential products and technology.
If
we choose to go to court to stop a third party from using the inventions claimed by our patents, that third party may ask the
court to rule that the patents are invalid and/or should not be enforced. Even if we were successful in stopping the infringing
activity, these lawsuits are expensive and could consume time and other resources. In addition, the court could decide that our
patents are not valid and that we do not have the right to stop others from making, using, or selling the inventions claimed by
the patents.
Additionally,
even if the validity of these patents is upheld, the court could refuse to stop a third party’s infringing activity on the
ground that such activities do not infringe our patents. The U.S. Supreme Court has recently revised certain tests regarding granting
patents and assessing the validity of patents, making it more difficult to obtain patents. As a consequence, issued patents may
be found to contain invalid claims according to the newly revised standards. Some of our patents may be subject to challenge and
subsequent invalidation or significant narrowing of claim scope in a reexamination proceeding, or during litigation, under the
revised criteria.
The
foregoing risks of third parties’ infringement of our intellectual property rights may be increased as we continue to engage
in discussions, collaborations, and other arrangements with third parties. New challenges also arise as we engage with third parties
located outside the United States. These factors could increase the risks and costs associated with building and protecting our
intellectual property portfolio.
Third
parties may claim that we infringe their proprietary rights and may prevent us from manufacturing and selling some or all of our
products.
The
manufacture, use and sale of new products that are the subject of conflicting patent rights have been the subject of substantial
litigation in the biotechnology industry relating to the validity and infringement of patents or proprietary rights of third parties.
Litigation may be costly and time-consuming and could divert the attention of our management and technical personnel. In addition,
if we infringe on the rights of others, we could lose our right to develop, manufacture, or market products or could be required
to pay monetary damages or royalties to license proprietary rights from third parties. Although the parties to patent and intellectual
property disputes in the biotechnology industry have often settled their disputes through licensing or similar arrangements, the
costs associated with these arrangements may be substantial and could include ongoing royalties. Furthermore, we cannot be certain
that the necessary licenses would be available to us on commercially reasonable terms or at all. These risks may be amplified
by our size relative to many of our competitors. As a result, an adverse determination in a judicial or administrative proceeding
or failure to obtain necessary licenses could prevent us from manufacturing and selling our products, and could have a material
adverse effect on our business, results of operations, financial condition, and cash flows.
If
we issue additional shares in the future, our existing stockholders will be diluted.
Our
articles of incorporation authorize the issuance of up to 160,000,000 shares of common stock with a par value of $0.0001 per share.
In addition to capital raising activities, other possible business and financial uses for our authorized common stock include,
without limitation, future stock splits, acquiring other companies, businesses, or products in exchange for shares of common stock,
issuing shares of our common stock to partners in connection with strategic alliances, attracting and retaining employees by the
issuance of additional securities under our various equity compensation plans, or other transactions and corporate purposes that
our Board of Directors deems are in the Company’s best interest. Additionally, shares of common stock could be used for
anti-takeover purposes or to delay or prevent changes in control or management of the Company. We cannot provide assurances that
any issuances of common stock will be consummated on favorable terms or at all, that they will enhance stockholder value, or that
they will not adversely affect our business or the trading price of our common stock. The issuance of any such shares will reduce
the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock.
If we issue any such additional shares, such issuance will reduce the proportionate ownership and voting power of all current
stockholders. Further, such issuance may result in a change of control of our company.
Sales
of common stock by our stockholders, or the perception that such sales may occur, could depress our stock price.
The
market price of our common stock could decline as a result of sales by, or the perceived possibility of sales by, our existing
stockholders. Since March 2011, we have completed a number of offerings of our common stock and warrants. Future sales of common
stock by significant stockholders, including by those who acquired their shares in our prior offerings, or through the exercise
of outstanding warrants, or who are affiliates, or the perception that such sales may occur, could depress the price of our common
stock.